FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Prasad Raju</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]						(Ch	eck all applic	or		10% Owner	
(Last)	,	irst) APEUTICS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/20/2024							helow)	(give title hief Finar	Other (s below) Officer	респу	
105 WEST FIRST STREET					4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	N M	A	02127											led by Mor		orting Person  One Repor	
(City)	(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication										
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				Beneficia	es Formally (D) (Following (I) (I		rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	Amou	nt (A) o	r Price	Transact (Instr. 3 a	ction(s)			(III3ti. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ative   Conversion   Date rity   or Exercise   (Month/Day/Year)   if any   C		Code (In	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  (Month/Day/Year)  7. Title and of Securitic Underlying Derivative (Instr. 3 and		ties ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				C	Code \	v	(A)	(D)	Date Exercisable	Expiration Date	n Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$72.94	03/20/2024			A		36,168		(1)	03/20/20.	4 Common Shares	36,168	\$0	36,168		D	
Restricted Stock Units	(2)	03/20/2024			A		25,000		(3)	(3)	Common Shares	25,000	\$0	25,000	)	D	

## **Explanation of Responses:**

- 1. This option was granted on March 20, 2024 with respect to 36,168 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 3. This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

/s/ AJ Silver, attorney-in-fact

03/22/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.